TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29370028

Group type: EXPERIMENTAL
Intervention: Thrombocytopenia (<150.000/mm) in cases with Type I ROP
Number of subjects: 81

Group type: COMPARATOR
Intervention: No thrombocytopenia in controls
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Bronchopulmonary dysplasia and thrombocytopenia
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Thrombocytopenia ratio
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Thrombocytopenia 1 week before intervention
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Platelet transfusion ratio
Number of subjects: 81
Study: 29474280

Group type: EXPERIMENTAL
Intervention: 200 mg of oral phenazopyridine
Number of subjects: 88

Group type: COMPARATOR
Intervention: No phenazopyridine (Control)
Number of subjects: 88
Study: 27209341

Group type: EXPERIMENTAL
Intervention: Hysteroscopic proximal tubal occlusion by intratubal devices
Number of subjects: 85

Group type: COMPARATOR
Intervention: Laparoscopic salpingectomy
Number of subjects: 85
Study: 24474086

Group type: EXPERIMENTAL
Intervention: DIC patients with elevated plasma CL-K1 levels
Number of subjects: 659

Group type: COMPARATOR
Intervention: Non-DIC patients
Number of subjects: 659

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 659
Study: 22412865

Group type: EXPERIMENTAL
Intervention: Late exposure group (LEG) - Sulfadoxine-Pyrimethamine (SP) plus Artesunate (AS) from 2.5-4.5 months of age and monthly placebo from 5.5-9.5 months
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Early exposure group (EEG) - Placebo from 2.5-4.5 months and SP+AS from 5.5-9.5 months
Number of subjects: 349

Group type: COMPARATOR
Intervention: Control group (CG) - Placebo from 2.5-9.5 months
Number of subjects: 349
Study: 20631460

Group type: EXPERIMENTAL
Intervention: Topical diclofenac sodium 1% gel (DSG) applied 4 g, 4 times daily
Number of subjects: 420

Group type: COMPARATOR
Intervention: Vehicle (control) applied 4 g, 4 times daily
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Topical diclofenac sodium 1% gel (DSG)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 420
Study: 17397001

Group type: EXPERIMENTAL
Intervention: peginterferon-alpha 2a/ribavirin therapy
Number of subjects: 31
Study: 15719490

Group type: EXPERIMENTAL
Intervention: Raltitrexed at a dose of 2.5 mg/m(2) intravenously (i.v), once every 3 weeks, for two doses, combined with standard radiotherapy of 70 Gy over 7 weeks.
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Raltitrexed at a dose of 2.5 mg/m(2) given twice 3 weeks apart, combined with 70 Gy of radiotherapy.
Number of subjects: 17
Study: 12112183

Group type: EXPERIMENTAL
Intervention: Sodium valproate 2 x 240 mg
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 10091405

Group type: EXPERIMENTAL
Intervention: (TA)7/(TA)7 genotype
Number of subjects: 60

Group type: COMPARATOR
Intervention: (TA)7/(TA)6 or (TA)6/(TA)6 genotypes
Number of subjects: 60
Study: 7749498

Group type: EXPERIMENTAL
Intervention: Standard intensive treatment and patient education with the distress reduction program
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard intensive treatment and patient education without the distress reduction program
Number of subjects: 23
Study: 2178909

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 0
Study: 373084

Group type: EXPERIMENTAL
Intervention: Tolfenamic acid 600 mg daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Phenylbutazone 300 mg daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Acetylsalicylic acid 1,500 mg daily
Number of subjects: 60
Study: 30551223

Group type: EXPERIMENTAL
Intervention: CPAP (Continuous Positive Airway Pressure)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 220
Study: 28009472

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg for 1 month (TP1)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg (TP2)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg (TP1)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (TP2)
Number of subjects: 44
Study: 25629710

Group type: EXPERIMENTAL
Intervention: Mobile app providing personalized sun protection advice
Number of subjects: 604
Study: 24651895

Group type: EXPERIMENTAL
Intervention: Glasses-based 3D monitor
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Mirror-based 3D display
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 3D displays (general)
Number of subjects: 48

Group type: COMPARATOR
Intervention: 2D HD display
Number of subjects: 48

Group type: COMPARATOR
Intervention: Autostereoscopic display
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 3D and 2D displays
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 3D display (general)
Number of subjects: 48
Study: 22846147

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) at 1 day before PPV
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) at 7 days before PPV
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB)
Number of subjects: 30
Study: 19753648

Group type: COMPARATOR
Intervention: G-CSF (5 microg/kg/day for 5-7 days)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Triple group (GM-CSF 10 microg/kg/day on 1st and 2nd day, G-CSF 5 microg/kg/day for 5-7 days, and darbepoetin-alpha 40 mg on 1st day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: G-CSF
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Triple group
Number of subjects: 30
Study: 17499604

Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg twice daily) + Esomeprazole (20 mg twice daily)
Number of subjects: 441

Group type: COMPARATOR
Intervention: Celecoxib (200 mg twice daily) + Placebo
Number of subjects: 441
Study: 15179107

Group type: EXPERIMENTAL
Intervention: Health screening, written feedback, and an optional follow-up visit with the general practitioner
Number of subjects: 1507

Group type: EXPERIMENTAL
Intervention: Health screening, written feedback, and a planned 45-min follow-up visit with the general practitioner
Number of subjects: 1507

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 1507
Study: 12468168

Group type: EXPERIMENTAL
Intervention: Lidocaine ointment
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Minor lacerations
Number of subjects: 200
Study: 9655734

Group type: EXPERIMENTAL
Intervention: Antioxidant vitamin supplementation (75 mg vitamin E, 650 mg vitamin C, 15 mg beta carotene)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 7649323

Group type: EXPERIMENTAL
Intervention: Adjuvant alpha‐interferon treatment (once a week for 8 weeks)
Number of subjects: 83

Group type: COMPARATOR
Intervention: No adjuvant interferon treatment (control group)
Number of subjects: 83
Study: 2501765

Group type: EXPERIMENTAL
Intervention: Insulin bolus (n = 24)
Number of subjects: 38

Group type: COMPARATOR
Intervention: No insulin bolus (n = 32)
Number of subjects: 38
Study: 588388

Group type: EXPERIMENTAL
Intervention: Pentolinium tartrate (Ansolysen) in doses of 10-15 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 29688121

Group type: EXPERIMENTAL
Intervention: RV3-BB vaccine (three doses, first dose at 0-5 days after birth)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: RV3-BB vaccine (three doses, first dose at about 8 weeks after birth)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo (placebo schedule)
Number of subjects: 96
Study: 28729014

Group type: EXPERIMENTAL
Intervention: Mannitol bladder distention
Number of subjects: 130

Group type: COMPARATOR
Intervention: Oral phenazopyridine
Number of subjects: 130

Group type: COMPARATOR
Intervention: Intravenous sodium fluorescein
Number of subjects: 130

Group type: COMPARATOR
Intervention: Normal saline bladder distention
Number of subjects: 130

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 130
Study: 26041585

Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 or 50 mg, depending on renal function)
Number of subjects: 388

Group type: COMPARATOR
Intervention: Glimepiride (titrated doses)
Number of subjects: 388
Study: 23337378

Group type: EXPERIMENTAL
Intervention: MGuard™ stent (MGS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bare metal stent (BMS)
Number of subjects: 40
Study: 22141471

Group type: EXPERIMENTAL
Intervention: Biomechanical visualisation software for ankle-foot orthosis tuning
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard care (tuning using observation alone)
Number of subjects: 70
Study: 18328440

Group type: EXPERIMENTAL
Intervention: Dietary counseling for regular homemade food
Number of subjects: 60

Group type: COMPARATOR
Intervention: Commercial MCT‐enriched dietary supplements
Number of subjects: 60
Study: 16556409

Group type: EXPERIMENTAL
Intervention: Fuzhenghuayu capsule
Number of subjects: 93

Group type: COMPARATOR
Intervention: Heluoshugan capsule
Number of subjects: 93
Study: 14630567

Group type: EXPERIMENTAL
Intervention: CDP860 (25 mg/kg)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study: 11550107

Group type: EXPERIMENTAL
Intervention: Chronic NSAID intake (n = 861)
Number of subjects: 3743

Group type: EXPERIMENTAL
Intervention: Active treatment (n = 2882)
Number of subjects: 3743

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3743
Study: 8899319

Group type: EXPERIMENTAL
Intervention: Ukrain
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no Ukrain)
Number of subjects: 10
Study: 1511192

Group type: EXPERIMENTAL
Intervention: Dry group (fluid administration: 50, 60, 70, 80, 90, 100 and 120 ml/kg/day during the first week and 150 ml/kg/day until aged four weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (fluid administration: 80, 100, 120 and 150 ml/kg/day during the first week and 200 ml/kg afterwards)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dry group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 6844664

Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 20
Study: 30160627

Group type: COMPARATOR
Intervention: LOW (9 weekly sets, 1 session per week)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: MOD (18 weekly sets, 2 sessions per week)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: HIGH (27 weekly sets, 2 sessions per week)
Number of subjects: 49
Study: 29979618

Group type: EXPERIMENTAL
Intervention: UVA decision support system (DSS)
Number of subjects: 24
Study: 27927145

Group type: EXPERIMENTAL
Intervention: Rock music
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Classical music
Number of subjects: 352

Group type: COMPARATOR
Intervention: Sound of an operating theatre
Number of subjects: 352
Study: 25844686

Group type: EXPERIMENTAL
Intervention: Circuit-based resistance training (CRT) for 8 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: No-exercise control group (CON)
Number of subjects: 18
Study: 23547239

Group type: EXPERIMENTAL
Intervention: Biomarker combinations centered on insulin‐like growth factor acid labile subunit
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 8 validated models combining various biomarkers
Number of subjects: 300
Study: 20970976

Group type: EXPERIMENTAL
Intervention: MK-0633 100 mg
Number of subjects: 266

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 266
Study: 18713501

Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (IPT) for 6 months, offered to 568 subjects, with 565 accepting.
Number of subjects: 1932

Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (IPT) with counseling and monthly follow-up.
Number of subjects: 1932

Group type: EXPERIMENTAL
Intervention: Non-completion reasons for 72 subjects: 24 (33%) physician-initiated due to active TB or side effects, 42 (58%) patient-initiated due to self-cessation or loss to follow-up, and 6 (8%) due to death unrelated to IPT.
Number of subjects: 1932
Study: 16540519

Group type: EXPERIMENTAL
Intervention: 3.5 ml of alcohol gel
Number of subjects: 84

Group type: COMPARATOR
Intervention: 1.75 ml of alcohol gel
Number of subjects: 84
Study: 14571789

Group type: EXPERIMENTAL
Intervention: Combination therapy with interferon alfa-2a (4.5 MU thrice weekly) and amantadine (200 mg daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Interferon therapy alone (4.5 MU thrice weekly)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination therapy with interferon alfa-2a and amantadine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Interferon therapy alone
Number of subjects: 30
Study: 10736080

Group type: COMPARATOR
Intervention: Epidural morphine (M)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Epidural morphine with butorphanol (M+B)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Butorphanol (B) 10 microg.kg‐1
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Butorphanol (B) 1.2 microg.kg‐1.h‐1
Number of subjects: 46
Study: 8726243

Group type: EXPERIMENTAL
Intervention: Pravastatin 5 mg/d
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg/d
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg/d
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Pravastatin (all doses)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 72
Study: 8180540

Group type: EXPERIMENTAL
Intervention: Integrated care
Number of subjects: 274

Group type: COMPARATOR
Intervention: Conventional hospital clinic care
Number of subjects: 274
Study: 3034623

Group type: EXPERIMENTAL
Intervention: Calcium entry blockers PY 108‐068 (PY)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium entry blockers PN 200‐110 (PN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29448135

Group type: EXPERIMENTAL
Intervention: Combined child-CBT (Coping Power Program) and Parent Management Training (PMT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Parent Management Training (PMT) only
Number of subjects: 120
Study: 25794636

Group type: EXPERIMENTAL
Intervention: Clinical Case Management with Problem-Solving Therapy (CM-PST)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Clinical Case Management (CM)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Combined CM and CM-PST
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: End of interventions to 12 weeks later
Number of subjects: 171
Study: 26576808

Group type: EXPERIMENTAL
Intervention: Meridian balanced method electroacupuncture (BMEA) + Traditional Chinese Medicine Health Consultation (TCM HC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine Health Consultation (TCM HC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 30
Study: 25353642

Group type: EXPERIMENTAL
Intervention: Femoropopliteal bypass
Number of subjects: 320

Group type: COMPARATOR
Intervention: Percutaneous transluminal angioplasty and stenting
Number of subjects: 320
Study: 21997893

Group type: EXPERIMENTAL
Intervention: Pediatric Hospitalists (PH)
Number of subjects: 279
Study: 20035187

Group type: EXPERIMENTAL
Intervention: gemcitabine/carboplatin
Number of subjects: 1135

Group type: EXPERIMENTAL
Intervention: gemcitabine/paclitaxel
Number of subjects: 1135

Group type: EXPERIMENTAL
Intervention: paclitaxel/carboplatin
Number of subjects: 1135

Group type: EXPERIMENTAL
Intervention: Patients with BM
Number of subjects: 1135

Group type: COMPARATOR
Intervention: Patients without BM
Number of subjects: 1135
Study: 17511363

Group type: EXPERIMENTAL
Intervention: 25-gauge needle
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: 27-gauge needle
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: 30-gauge needle
Number of subjects: 810

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 810
Study: 16187618

Group type: EXPERIMENTAL
Intervention: Wide design (MCA)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1SR design (MCA)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 2SR design (MCA)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Thick design (MCA)
Number of subjects: 10
Study: 12685514

Group type: EXPERIMENTAL
Intervention: Trandolapril (Tra) 2 mg
Number of subjects: 92

Group type: COMPARATOR
Intervention: Quinapril (Qui) 20 mg
Number of subjects: 92
Study: 10073329

Group type: EXPERIMENTAL
Intervention: OROS oxybutynin chloride 5 mg once daily for 4 days
Number of subjects: 13

Group type: COMPARATOR
Intervention: Immediate-release oxybutynin 5 mg every 8 hours for 4 days
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: OROS oxybutynin chloride
Number of subjects: 13
Study: 8839195

Group type: EXPERIMENTAL
Intervention: Ultra-high-dose streptokinase
Number of subjects: 77

Group type: COMPARATOR
Intervention: Conventional-dose streptokinase
Number of subjects: 77
Study: 14621759

Group type: EXPERIMENTAL
Intervention: CMV-Polyglobulin (2 ml/kg body weight)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intraglobin (15 g)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No specific anti-CMV prophylaxis (Control group)
Number of subjects: 120
Study: 3935486

Group type: EXPERIMENTAL
Intervention: 19NT-hexoxyphenylpropionate (19NT-HPP), 200 mg/week intramuscularly for 7 weeks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 19NT-hexoxyphenylpropionate (19NT-HPP) given every 3 weeks
Number of subjects: 12
Study: 31272399

Group type: EXPERIMENTAL
Intervention: Text message support intervention (4 messages/week for 6 months)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 160
Study: 29539274

Group type: EXPERIMENTAL
Intervention: Oral regimen (fluconazole 1200 mg/day plus flucytosine 100 mg/kg/day for 2 weeks)
Number of subjects: 721

Group type: EXPERIMENTAL
Intervention: 1-week amphotericin B (1 mg/kg/day)
Number of subjects: 721

Group type: COMPARATOR
Intervention: 2-week amphotericin B (1 mg/kg/day)
Number of subjects: 721

Group type: EXPERIMENTAL
Intervention: Flucytosine as partner drug with amphotericin B
Number of subjects: 721

Group type: EXPERIMENTAL
Intervention: 1-week amphotericin B plus flucytosine
Number of subjects: 721
Study: 30640987

Group type: EXPERIMENTAL
Intervention: Chinese herbal fumigation combined with leflunomide (20 mg) and prednisone (15 mg) once per day for 6 months
Number of subjects: 99

Group type: COMPARATOR
Intervention: Western drugs (leflunomide and prednisone)
Number of subjects: 99
Study: 25007725

Group type: EXPERIMENTAL
Intervention: Combined intravenous (IV) and topical application of tranexamic acid (TXA): 1.5 g topical TXA + 1.5 g IV-TXA
Number of subjects: 184

Group type: COMPARATOR
Intervention: Intravenous tranexamic acid (IV-TXA): 3 g
Number of subjects: 184
Study: 22505603

Group type: EXPERIMENTAL
Intervention: Buprenorphine 180 µg/m(2) with carprofen 4 mg/kg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Buprenorphine 180 µg/m(2) with meloxicam 0.3 mg/kg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Butorphanol 6 mg/m(2) with carprofen 4 mg/kg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Butorphanol 6 mg/m(2) with meloxicam 0.3 mg/kg
Number of subjects: 100
Study: 20440550

Group type: EXPERIMENTAL
Intervention: Mindfulness and yoga intervention (12-week duration)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 97
Study: 17919272

Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 33

Group type: COMPARATOR
Intervention: Octreotide
Number of subjects: 33
Study: 16041635

Group type: EXPERIMENTAL
Intervention: Sterile water gavage drip (SWGD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional intravenous fluid management
Number of subjects: 60
Study: 12394909

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic brain stimulation after treadmill challenge (four stimuli per minute) until disappearance of symptoms
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (12 subjects)
Number of subjects: 42
Study: 10089845

Group type: EXPERIMENTAL
Intervention: ICD therapy
Number of subjects: 50000

Group type: EXPERIMENTAL
Intervention: ICD implantation
Number of subjects: 50000

Group type: COMPARATOR
Intervention: ICD usage
Number of subjects: 50000
Study: 7751709

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (10 mg/kg/day by continuous intravenous infusion)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control (standard quinine regimen without pentoxifylline)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control
Number of subjects: 56
Study: 1529900

Group type: EXPERIMENTAL
Intervention: Echocardiographic low-risk identification procedure
Number of subjects: 195

Group type: COMPARATOR
Intervention: Clinical low-risk identification procedure
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Combined echocardiographic and clinical evaluations
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Echocardiographic examination
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Echocardiographic studies
Number of subjects: 195
Study: 6363492

Group type: EXPERIMENTAL
Intervention: Triamterene-hydrochlorothiazide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spironolactone-hydrochlorothiazide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 0
Study: 30350477

Group type: EXPERIMENTAL
Intervention: Dasiglucagon 0.03 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Dasiglucagon 0.08 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Dasiglucagon 0.2 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Dasiglucagon 0.6 mg
Number of subjects: 17

Group type: COMPARATOR
Intervention: Commercial glucagon (Eli Lilly) 0.03 mg
Number of subjects: 17

Group type: COMPARATOR
Intervention: Commercial glucagon (Eli Lilly) 0.08 mg
Number of subjects: 17

Group type: COMPARATOR
Intervention: Commercial glucagon (Eli Lilly) 0.2 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Dasiglucagon 0.03 mg in hypoglycaemia
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Dasiglucagon 0.08 mg in hypoglycaemia
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Dasiglucagon (all doses)
Number of subjects: 17